Saamya Biotech (India) was incorporated as a public limited company on August 13, 2002 and certificate of commencement of business was issued on August 26, 2002. The promoters of the company are Dr. Y. Manivardhan Reddy and Dr. Y. Sonia Reddy and it is engaged in business of manufacturing, import, export and dealing in all types of chemicals pharmaceuticals drugs and intermediates.
Saamya Biotech (India) (SBIL) is a new generation biotechnology company incorporated in India (Hyderabad) with the aim to manufacture and market biopharmaceuticals and recombinant protein products of medical and industrial importance, and also to discover and develop emerging biotech products of far reaching significance. The company proposes to set up world class facilities for the manufacture of fermentation based high value biotech products. The company embarks on developing effective strategies for the production and supply of both bulk and formulations with special focus on life saving drug entities at affordable price.
The company has entered into technology transfer agreement with Biofin laboratories s.r.l Italy for technology know-how to manufacture bio-pharmaceutical ingredients.
The company entered into sales and purchase agreement with Finchimica, Italy on September 18, 2004, in terms of which Finchimica, Italy would buy all the products manufactured by it to the extent of 100%.
Product range off the company includes:
- Daunomycin
- Hyaluronic acid (Pharma grade)
- Tacrolimus and Rapamycin
- Cyclosporin A, Probiotics
- Lysergic acid
- Mycophenolic acid
- Clavulenic acid
- Vancomycin
- Co-enzyme Q10
- Interferon β
- Monoclonal antibodies (anti-cancer).
| 